Kingdon Capital Management, L.L.C. Cytokinetics Inc Transaction History
Kingdon Capital Management, L.L.C.
- $834 Million
- Q3 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Cytokinetics Inc stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 266,700 shares of CYTK stock, worth $13.2 Million. This represents 1.69% of its overall portfolio holdings.
Number of Shares
266,700
Previous 266,700
-0.0%
Holding current value
$13.2 Million
Previous $14.4 Million
2.55%
% of portfolio
1.69%
Previous 1.68%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
410Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$724 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$581 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$478 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$384 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$319 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.65B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...